MA38090A1 - Dérivés de 5-fluoro-n-(pyridin -2-yl)pyridin-2-amines contenant un groupe sulfoximine - Google Patents

Dérivés de 5-fluoro-n-(pyridin -2-yl)pyridin-2-amines contenant un groupe sulfoximine

Info

Publication number
MA38090A1
MA38090A1 MA38090A MA38090A MA38090A1 MA 38090 A1 MA38090 A1 MA 38090A1 MA 38090 A MA38090 A MA 38090A MA 38090 A MA38090 A MA 38090A MA 38090 A1 MA38090 A1 MA 38090A1
Authority
MA
Morocco
Prior art keywords
pyridin
fluoro
derivatives
sulfoximine group
amines containing
Prior art date
Application number
MA38090A
Other languages
English (en)
Other versions
MA38090B1 (fr
Inventor
Gerhard Siemeister
Philip Lienau
Ulf Bömer
Ludwig Zorn
Rolf Bohlmann
Ulrich Lücking
Niels Böhnke
Arne Scholz
Dirk Kosemund
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA38090A1 publication Critical patent/MA38090A1/fr
Publication of MA38090B1 publication Critical patent/MA38090B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des dérivés de 5-fluoro-n-(pyridin-2-yl)pyridin-2-amines contenant un groupe sulfoximine de formule générale (i), comme défini et indiqué dans la description; et des méthodes pour les préparer et les utiliser pour le traitement et/ou la prévention de troubles, en particulier de troubles hyperprolifératifs et/ou de maladies infectieuses d'origine virale et/ou de maladies cardiovasculaires. L'invention concerne également des composés intermédiaires utiles pour la préparation des composés de formule générale (i).
MA38090A 2012-11-15 2013-11-12 Dérivés de 5-fluoro-n-(pyridin -2-yl)pyridin-2-amines contenant un groupe sulfoximine MA38090B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12192852 2012-11-15
PCT/EP2013/073637 WO2014076091A1 (fr) 2012-11-15 2013-11-12 Dérivés de 5-fluoro-n-(pyridin -2-yl)pyridin-2-amines contenant un groupe sulfoximine

Publications (2)

Publication Number Publication Date
MA38090A1 true MA38090A1 (fr) 2018-02-28
MA38090B1 MA38090B1 (fr) 2018-09-28

Family

ID=47148672

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38090A MA38090B1 (fr) 2012-11-15 2013-11-12 Dérivés de 5-fluoro-n-(pyridin -2-yl)pyridin-2-amines contenant un groupe sulfoximine

Country Status (42)

Country Link
US (2) US9650340B2 (fr)
EP (1) EP2928878B1 (fr)
JP (1) JP6263193B2 (fr)
KR (1) KR102242871B1 (fr)
CN (1) CN105102444B (fr)
AP (1) AP3872A (fr)
AR (1) AR093505A1 (fr)
AU (1) AU2013346939B2 (fr)
BR (1) BR112015010707B1 (fr)
CA (1) CA2891358C (fr)
CL (1) CL2015001304A1 (fr)
CR (1) CR20150256A (fr)
CU (1) CU20150052A7 (fr)
CY (1) CY1118441T1 (fr)
DK (1) DK2928878T3 (fr)
DO (1) DOP2015000118A (fr)
EA (1) EA027226B1 (fr)
EC (1) ECSP15019323A (fr)
ES (1) ES2612978T3 (fr)
HR (1) HRP20161547T1 (fr)
HU (1) HUE032868T2 (fr)
IL (1) IL238322A (fr)
JO (1) JO3332B1 (fr)
LT (1) LT2928878T (fr)
MA (1) MA38090B1 (fr)
ME (1) ME02880B (fr)
MX (1) MX374333B (fr)
MY (1) MY170609A (fr)
NZ (1) NZ707084A (fr)
PE (1) PE20151071A1 (fr)
PH (1) PH12015501003B1 (fr)
PL (1) PL2928878T3 (fr)
PT (1) PT2928878T (fr)
RS (1) RS55580B1 (fr)
SG (1) SG11201503079PA (fr)
SI (1) SI2928878T1 (fr)
SV (1) SV2015004979A (fr)
TN (1) TN2015000185A1 (fr)
TW (1) TWI613193B (fr)
UA (1) UA115254C2 (fr)
UY (1) UY35141A (fr)
WO (1) WO2014076091A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
TW201636330A (zh) 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
ES2616441T3 (es) 2012-10-18 2017-06-13 Bayer Pharma Aktiengesellschaft Derivados de N-(piridin-2-il))pirimidin-4-amina que contienen un grupo sulfona
HK1209414A1 (en) 2012-10-18 2016-04-01 Bayer Pharma Aktiengesellschaft 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物
ME02880B (fr) 2012-11-15 2018-04-20 Bayer Pharma AG Dérivés de 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine contenant un groupe de sulfoximines
HUE032891T2 (hu) 2012-12-17 2017-11-28 Parion Sciences Inc Klórpirazin-karboxamid-származékok nem kielégítõ nyálkahártya-hidratáció által elõsegített megbetegedések kezelésére
RU2671976C2 (ru) 2012-12-17 2018-11-08 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида
EP3016945B1 (fr) * 2013-07-04 2017-05-03 Bayer Pharma Aktiengesellschaft Dérivés de 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine substitués par sulfoximine et leurs utilisation en tant qu'inhibiteurs de kinase cdk9
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
US9856242B2 (en) 2014-03-13 2018-01-02 Bayer Pharma Aktiengesellscaft 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
EP3126338B1 (fr) 2014-04-01 2019-09-04 Bayer Pharma Aktiengesellschaft Dérivés de 5-fluoropyrimidine disubstitués contenant un groupe sulfone diimine
US9963464B2 (en) 2014-04-11 2018-05-08 Bayer Pharma Aktiengesellschaft Macrocyclic compounds
CN107001341B (zh) 2014-10-16 2020-08-07 拜耳医药股份有限公司 含有磺亚胺基的氟化苯并呋喃基-嘧啶衍生物
CA2964683A1 (fr) 2014-10-16 2016-04-21 Bayer Pharma Aktiengesellschaft Derives de benzofuranyle-pyrimidine fluores contenant un groupe sulfone
JP6847099B2 (ja) 2015-09-29 2021-03-24 バイエル ファーマ アクチエンゲゼルシャフト 新規な大環状スルホンジイミン化合物
ES2819869T3 (es) 2015-10-08 2021-04-19 Bayer Pharma AG Nuevos compuestos macrocíclicos modificados
WO2017060322A2 (fr) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Conjugué anticorps-médicament (adc) inhibiteur de ptefb
CA3057891A1 (fr) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Nouveaux composes macrocycliques inhibiteurs de ptefb
EP3601253B1 (fr) 2017-03-28 2021-09-15 Bayer Aktiengesellschaft Nouveaux composés macrocycliques inhibiteurs de ptefb
US11701347B2 (en) * 2018-02-13 2023-07-18 Bayer Aktiengesellschaft Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large B-cell lymphoma
AU2020401999B2 (en) 2019-12-09 2024-01-18 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Compound as cyclin-dependent kinase 9 inhibitor and use thereof
CA3174507A1 (fr) * 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Imidazotriazines agissant sur le cancer par inhibition de cdk12
WO2022078309A1 (fr) * 2020-10-12 2022-04-21 上海海雁医药科技有限公司 Dérivé de bis(pyridin-2-yl)amine substitué, sa composition et son utilisation médicale
WO2023179597A1 (fr) * 2022-03-25 2023-09-28 成都苑东生物制药股份有限公司 Dérivé d'aminopyridine, son procédé de préparation et son utilisation
WO2024044757A1 (fr) * 2022-08-26 2024-02-29 Sanford Burnham Prebys Medical Discovery Institute Dérivés d'aminopyrimidine et d'aminotriazine utilisés en tant que modulateurs de la protéine myc
EP4611750A1 (fr) * 2022-11-02 2025-09-10 Vincerx Pharma, Inc. Polythérapies comprenant un inhibiteur cdk9 contre le cancer
WO2024112656A1 (fr) * 2022-11-21 2024-05-30 The Board Of Trustees Of The Leland Stanford Junior University Utilisation d'un inhibiteur de tyrosine kinase pour le traitement de la télangiectasie hémorragique héréditaire et de l'hypertension artérielle pulmonaire

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03005696A (es) 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DE10349423A1 (de) * 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US20090099160A1 (en) 2004-12-17 2009-04-16 David Andrews 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors
DE102006041382A1 (de) * 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
WO2008060248A1 (fr) 2006-11-15 2008-05-22 S*Bio Pte Ltd. Pyrimidines substituées par indole, et leur utilisation dans le traitement d'un cancer
EP2094682A2 (fr) 2006-12-22 2009-09-02 Novartis AG Composés organiques et leurs utilisations
EP2094681A1 (fr) 2006-12-22 2009-09-02 Novartis AG Dérivés d'indol-4-yl-pyrimidinyl-2-yl-amine et leur utilisation comme inhibiteurs de la kinase dépendante des cyclines
JP5379787B2 (ja) 2007-04-24 2013-12-25 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤
EP2137166B1 (fr) 2007-04-24 2012-05-30 Ingenium Pharmaceuticals GmbH Dérivés d'aminopyrimidines 4,6 disubstitués comme inhibiteurs de protéine kinase
ES2539518T3 (es) 2007-04-24 2015-07-01 Astrazeneca Ab Inhibidores de proteínas quinasas
WO2008132138A1 (fr) 2007-04-25 2008-11-06 Ingenium Pharmaceuticals Gmbh Dérivés d'aminopyrimidines disubstituées en 4 et en 6
WO2009029998A1 (fr) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Composés rétrométaboliques
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
CA2789200C (fr) 2010-03-22 2020-05-26 Lead Discovery Center Gmbh Derives de triazine disubstitues pharmaceutiquement actifs
WO2012101063A1 (fr) * 2011-01-28 2012-08-02 Novartis Ag Composés de n-acyl pyridine biaryl et leurs utilisations
JP5947818B2 (ja) * 2011-03-02 2016-07-06 リード ディスカバリー センター ゲーエムベーハー 薬学的活性化二置換ピリジン誘導体
EP2527332A1 (fr) * 2011-05-24 2012-11-28 Bayer Intellectual Property GmbH 4-Aryl-N-phényl-1,3,5-triazin-2-amines portant un groupe sulfoximine en tant qu'inhibiteurs de CDK9
CN103917527B (zh) 2011-09-16 2017-05-31 拜耳知识产权有限责任公司 二取代的5‑氟‑嘧啶
CN103930399B (zh) 2011-09-16 2016-03-16 拜耳知识产权有限责任公司 包含亚氨基亚磺酰基的二取代的5-氟嘧啶衍生物
CN105102434A (zh) 2012-10-18 2015-11-25 拜耳药业股份公司 含砜基团的4-(邻)-氟苯基-5-氟嘧啶-2-基胺
HK1209414A1 (en) * 2012-10-18 2016-04-01 Bayer Pharma Aktiengesellschaft 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
WO2014076028A1 (fr) 2012-11-15 2014-05-22 Bayer Pharma Aktiengesellschaft 4-(ortho)-fluorophényl)-5-fluoropyrimidin-2-yl amines contenant un groupe sulfoximine
ME02880B (fr) 2012-11-15 2018-04-20 Bayer Pharma AG Dérivés de 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine contenant un groupe de sulfoximines
EP3016945B1 (fr) 2013-07-04 2017-05-03 Bayer Pharma Aktiengesellschaft Dérivés de 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine substitués par sulfoximine et leurs utilisation en tant qu'inhibiteurs de kinase cdk9
US9856242B2 (en) 2014-03-13 2018-01-02 Bayer Pharma Aktiengesellscaft 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group

Also Published As

Publication number Publication date
CN105102444B (zh) 2017-08-01
BR112015010707A8 (pt) 2019-10-01
EA027226B1 (ru) 2017-07-31
NZ707084A (en) 2019-09-27
UY35141A (es) 2014-06-30
JO3332B1 (ar) 2019-03-13
ME02880B (fr) 2018-04-20
AU2013346939B2 (en) 2017-06-08
CR20150256A (es) 2015-07-01
TWI613193B (zh) 2018-02-01
ECSP15019323A (es) 2016-01-29
DK2928878T3 (en) 2016-12-19
PE20151071A1 (es) 2015-08-19
AU2013346939A1 (en) 2015-05-14
TW201420569A (zh) 2014-06-01
IL238322A (en) 2017-08-31
US9877954B2 (en) 2018-01-30
BR112015010707A2 (pt) 2017-07-11
DOP2015000118A (es) 2015-06-15
SV2015004979A (es) 2017-01-30
SI2928878T1 (sl) 2016-12-30
JP2015537015A (ja) 2015-12-24
BR112015010707B1 (pt) 2022-05-17
KR102242871B1 (ko) 2021-04-20
MY170609A (en) 2019-08-20
CL2015001304A1 (es) 2015-07-17
MA38090B1 (fr) 2018-09-28
SG11201503079PA (en) 2015-06-29
RS55580B1 (sr) 2017-06-30
CA2891358A1 (fr) 2014-05-22
PT2928878T (pt) 2017-02-08
PH12015501003B1 (en) 2017-10-20
AP3872A (en) 2016-10-31
CA2891358C (fr) 2021-05-18
WO2014076091A1 (fr) 2014-05-22
AP2015008432A0 (en) 2015-05-31
UA115254C2 (uk) 2017-10-10
CN105102444A (zh) 2015-11-25
CY1118441T1 (el) 2017-06-28
PL2928878T3 (pl) 2017-04-28
LT2928878T (lt) 2016-11-25
US20150291528A1 (en) 2015-10-15
AR093505A1 (es) 2015-06-10
HK1213255A1 (zh) 2016-06-30
HRP20161547T1 (hr) 2016-12-30
EP2928878A1 (fr) 2015-10-14
TN2015000185A1 (en) 2016-10-03
EP2928878B1 (fr) 2016-11-02
IL238322A0 (en) 2015-06-30
PH12015501003A1 (en) 2015-07-27
KR20150084968A (ko) 2015-07-22
US20170202815A1 (en) 2017-07-20
EA201590890A1 (ru) 2015-11-30
ES2612978T3 (es) 2017-05-19
US9650340B2 (en) 2017-05-16
MX374333B (es) 2025-03-06
MX2015006169A (es) 2015-08-10
HUE032868T2 (en) 2017-11-28
CU20150052A7 (es) 2015-09-29
JP6263193B2 (ja) 2018-01-17

Similar Documents

Publication Publication Date Title
MA38090B1 (fr) Dérivés de 5-fluoro-n-(pyridin -2-yl)pyridin-2-amines contenant un groupe sulfoximine
MA38091A2 (fr) Dérivés n-(pyridin-2-yl)pyrimidin-4-amines contenant un groupe sulfoximine
MA35132B1 (fr) 4-aryl-n-phényl-1,3,5-triazine-2- amines contenant un groupe sulfoximine
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
MA37798B1 (fr) 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes
MA35039B1 (fr) Dérivés ramifiés de l'acide 3-phénylpropionique et leur utilisation
MA37519B1 (fr) Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
MA34896B1 (fr) Inhibiteurs du virus de l'hepatite c
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
MA33509B1 (fr) Dérivés de l'oxazine et leur utilisation dans le traitement de troubles neurologiques
MA37942A2 (fr) Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b
MA34397B1 (fr) Dérivés d'acide napht-2-ylacétique dans le traitement du sida
MA42230A (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA34727B1 (fr) Imidazolylimidazoles condensés utilisés comme composés antiviraux
MA38146A1 (fr) Nouveaux dérivés du benzimidazole comme antagonistes ep4
MA35444B1 (fr) Ligands du récepteur ep1
WO2008152099A3 (fr) Aryl/hétarylamides en tant que modulateurs du récepteur ep2
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
PH12013501089A1 (en) Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2
MA35104B1 (fr) Inhibiteur du virus de l'hepatite c
CA2878796C (fr) Derives de pyridinone comme inhibiteurs de la transglutaminase tissulaire
FR3041639B1 (fr) NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
ATE554076T1 (de) Sulfoximinsubstituierte chinazolinderivate als immunmodulatoren, ihre herstellung und ihre verwendung als medikamente
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA34910B1 (fr) Dérivés de 2-methoxy-pyridin-4-yl